種瀬 啓士 (タネセ ケイジ)

Tanese, Keiji

写真a

所属(所属キャンパス)

医学部 皮膚科学教室 (信濃町)

職名

専任講師(有期)

学歴 【 表示 / 非表示

  • 1995年04月
    -
    2001年03月

    慶應義塾大学, 医学部

    大学, 卒業

  • 2003年04月
    -
    2007年03月

    慶應義塾大学, 医学部, 皮膚科学教室・医学系大学院博士課程

    大学院, 卒業, 博士

学位 【 表示 / 非表示

  • 医学博士, 慶應義塾大学, 課程, 2009年02月

    13. Tanese K, Fukuma M, Yamada T, Mori T, Yoshikawa T, Watanabe W, Ishiko A, Amagai M, Nishikawa T, Sakamoto M. G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. The American journal of pathology. 2008;173(3):835-43.

免許・資格 【 表示 / 非表示

  • 医師免許, 2001年05月

  • 日本皮膚科学会皮膚科専門医, 2008年10月

 

研究分野 【 表示 / 非表示

  • 皮膚科学

研究キーワード 【 表示 / 非表示

  • 皮膚病理学

  • 腫瘍医学

  • 腫瘍病理学

  • 薬事行政

研究テーマ 【 表示 / 非表示

  • 悪性黒色腫における腫瘍微小周囲環境の解析, 

    2013年
    -
    継続中

 

論文 【 表示 / 非表示

  • Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells

    Imaoka M., Tanese K., Masugi Y., Hayashi M., Sakamoto M.

    Cancer Science (Cancer Science)  110 ( 7 ) 2273 - 2283 2019年07月

    ISSN  13479032

     概要を見る

    © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. Expression of programmed cell death ligand 1 (PD-L1) on tumor cells contributes to cancer immune evasion by interacting with programmed cell death 1 on immune cells. γ-Interferon (IFN-γ) has been reported as a key extrinsic stimulator of PD-L1 expression, yet its mechanism of expression is poorly understood. This study analyzed the role of CD74 and its ligand macrophage migration inhibitory factor (MIF) on PD-L1 expression, by immunohistochemical analysis of melanoma tissue samples and in vitro analyses of melanoma cell lines treated with IFN-γ and inhibitors of the MIF-CD74 interaction. Immunohistochemical analyses of 97 melanoma tissue samples showed significant correlations between CD74 and the expression status of PD-L1 (P <.01). In vitro analysis of 2 melanoma cell lines, which are known to secrete MIF constitutively and express cell surface CD74 following IFN-γ stimulation, showed upregulation of PD-L1 levels by IFN-γ stimulation. This was suppressed by further treatment with the MIF-CD74 interaction inhibitor, 4-iodo-6-phenylpyrimidine. In the analysis of melanoma cell line WM1361A, which constitutively expresses PD-L1, CD74, and MIF in its non-treated state, treatment with 4-iodo-6-phenylpyrimidine and transfection of siRNAs targeting MIF and CD74 significantly suppressed the expression of PD-L1. Together, the results indicated that MIF-CD74 interaction directly regulated the expression of PD-L1 and helps tumor cells escape from antitumorigenic immune responses. In conclusion, the MIF-CD74 interaction could be a therapeutic target in the treatment of melanoma patients.

  • Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab

    Umezawa Y., Torisu-Itakura H., Morisaki Y., ElMaraghy H., Nakajo K., Akashi N., Saeki H., Akasaka T., Asano Y., Etoh T., Fujita Y., Hashimoto T., Higashiyama M., Igarashi A., Ihn H., Iwatsuki K., Kabashima K., Kawada A., Kawashima M., Nakamura K., Okubo Y., Okuyama R., Ozawa A., Sayama K., Seishima M., Shiohara T., Takahara M., Takahashi H., Takehara K., Tanese K., Tani M., Watanabe H., Yamanaka K.

    Journal of the European Academy of Dermatology and Venereology (Journal of the European Academy of Dermatology and Venereology)  33 ( 3 ) 568 - 576 2019年03月

    査読有り,  ISSN  09269959

     概要を見る

    © 2018 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. Background: Long-term management of moderate-to-severe psoriasis is usually discussed in terms of continuous administration; however, there are many situations in clinical practice where treatment may be withdrawn with subsequent retreatment. Objective: To assess the clinical course after ixekizumab treatment withdrawal and retreatment, as well as the effectiveness of ixekizumab retreatment, in Japanese patients with plaque psoriasis. Methods: This single-arm, open-label study (UNCOVER-J; NCT01624233) comprised 78 patients with plaque psoriasis. After ixekizumab treatment (160-mg loading dose, 80 mg every 2 weeks for the first 12 weeks, and then 80 mg every 4 weeks (IXE Q4W) until Week 52), 70 patients achieved a Psoriasis Area Severity Index (PASI)75 response at Week 52. These 70 patients withdrew from ixekizumab treatment from Weeks 52 to 100. Patients who relapsed (PASI ≤50) during the Treatment Withdrawal Period were retreated with IXE Q4W for 192 weeks. Results: At Weeks 52, 76 and 100, PASI75 response rates were 100%, 26% and 7%; PASI90 response rates were 87%, 11% and 3%; and PASI100 response rates were 53%, 0% and 0%. After treatment withdrawal, 87% of patients relapsed; median time to relapse was 143 days. After 12 weeks of retreatment with IXE Q4W, 83% of relapsed patients achieved PASI75, 68% achieved PASI90 and 25% achieved PASI100; improvements were maintained up to 120 weeks of retreatment. Treatment-emergent adverse events and serious adverse events were reported in 56% and 4% of patients during the Treatment Withdrawal Period, and in 88% and 14% of patients during the Retreatment Period. Conclusion: In patients withdrawn from ixekizumab after achieving PASI75, approximately half relapsed within 5 months of withdrawal; however, most patients recaptured response within 12 weeks, and response was maintained for up to 120 weeks of retreatment.

  • Gamma-delta T cell large granular lymphocyte leukaemia with multiple cutaneous nodules that showed spontaneous regression

    Suzuki C, Hirai I, Nomura H, Ouchi T, Okayama M, Okamoto S, Amagai M, Tanese K, Takahashi H

    J Eur Acad Dermatol Venereol 33 ( 3 ) e134 - e137 2019年03月

    共著, 査読有り,  ISSN  0926-9959

  • Congenital nail clubbing

    Nakazawa S, Niizeki H, Nakabayashi K, Tanese K, Tokura Y

    J Dermatol 46 ( 3 ) e101 - e102 2019年03月

    共著, 査読有り,  ISSN  0385-2407

  • Poromas with large lumens histopathologically mimicking syringocystadenoma papilliferum: Report of three cases

    Arakawa H., Tanese K., Miura K., Ebata S., Yamada D., Masui Y., Tanaka M., Saida T., Ansai S.

    Australasian Journal of Dermatology (Australasian Journal of Dermatology)  60 ( 1 ) e51 - e55 2019年02月

    共著, 査読有り,  ISSN  00048380

     概要を見る

    © 2018 The Australasian College of Dermatologists We report on three patients exhibiting tumours with exophytic pedunculated structures with eroded surfaces. All cases showed the basic histopathological features of poroma accompanied by large, invaginated ductal structures lined by multiple layers of columnar or cuboidal cells. The columnar cells of invaginated ductal/cystic structures focally exhibited subtle features reminiscent of decapitation secretion along with dense infiltration of plasma cells in the surrounding stroma, mimicking syringocystadenoma papilliferum.

全件表示 >>

総説・解説等 【 表示 / 非表示

全件表示 >>

研究発表 【 表示 / 非表示

  • 悪性黒色種の副腎転移病変に対し動脈化学塞栓療法が奏効した1例

    田原海, 中村善雄, 平井郁子, 種瀬啓士, 天谷雅行, 小黒草太, 舩越建

    第882回日本皮膚科学会東京地方会(城西地区) (東京) , 2019年01月

  • Efficacy and safety of weekly docetaxel regimen for advanced extramammary Paget’s disease: retrospective single institute analysis

    Nakamura Y, Hirai I, Ishii M, Tanese K, Kawakami Y, Funakoshi T

    European Sosciety for Medical Oncology Asia Congress 2018 (Singapore, Singapore) , 2018年11月

  • Analysis of The Appropriate Margin of Pigmented BCC: A Single Institute Retrospective Study In Japan

    Nakamura Y, Tanese K, Hirai I, Kameyama K, Kawakami Y, Amagai M, Funakoshi T

    17th World Congress on Cancers of the Skin 2018 (Sydney, Australia) , 2018年08月

  • Analysis of HER2 expression in metastatic extramammary Paget’s disease

    Hirai I, Tanese K, Nakamura Y, Otsuka A, Fujisawa Y, Yamamoto Y, Hata H, Fujimura T, Matsushita S, Yoshino K, Kameyama K, Amagai M, Funakoshi T

    17th World Congress on Cancers of the Skin 2018 (Sydney, Australia) , 2018年08月

  • Retrospective Study of Chemotherapy Using Carboplatin and Epirubicin for Advanced Epithelial Malignancy of the Skin

    Nakamura Y, Tanese K, Hirai I, Kawakami Y, Amagai M, Funakoshi T

    17th World Congress on Cancers of the Skin 2018 (Sydney, Australia) , 2018年08月

全件表示 >>